Study of Radiotherapy Combined with Concurrent Paclitaxel Liposome or Cisplatin in Elderly Patients with Cervical Cancer

Shi, Fan; Liu, Z.; Wang, J.; Wang, T.

doi:10.1016/j.ijrobp.2020.07.2302

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the treatment of CESC and HNSC is surgery combined with adjuvant radiotherapy or radical radiation therapy ( 5 ). However, the five-year progression-free survival rate of CESC patients treated with radiotherapy and the two-year progression-free survival rate of HNSC patients treated with combined radiotherapy and cisplatin are only 43.6 ( 6 ) and 41% ( 7 ), respectively. Relapse, which causes radiotherapy failure in CESC and HNSC, is primarily attributed to radioresistance.…”

Section: Introductionmentioning

confidence: 98%

FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration

Huang

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Radiotherapy is one of the standard treatments for cervical cancer and head and neck cancer. However, the clinical efficacy of this treatment is limited by radioresistance. The discovery of effective prognostic biomarkers and the identification of new therapeutic targets have helped to overcome the problem of radioresistance. In this study, we show that in the context of PIK3CA mutation or amplification, high expression of fascin actin-bundling protein 1 (FSCN1) (using the median as the cut-off value) is associated with poor prognosis and radiotherapy response in cancer patients. Silencing FSCN1 enhances radiosensitivity and promotes apoptosis in cancer cells with PIK3CA alterations, and this process may be associated with the downregulation of YWHAZ. These results reveal that FSCN1 may be a key regulator of radioresistance and could be a potential target for improving radiotherapy efficacy in cervical cancer and head and neck cancer patients with PIK3CA alterations.

show abstract

Section: Introductionmentioning

confidence: 98%